Article Text

PDF
Venous thromboembolic disease and cancer
  1. A Fennerty
  1. Correspondence to:
 A Fennerty
 Harrogate District Foundation Trust, Lancaster Park Road, Harrogate HG2 7SX, UK; Anthony.Fennerty{at}hdft.nhs.uk

Abstract

Venous thromboembolic disease is a common cause of mortality and morbidity in patients with cancer. Patients have a 5–6-fold increase in the risk for a venous thromboembolism (VTE) compared with the general population, increasing to 6–7-fold for some cancers. Prophylaxis for VTE should be considered whenever additional risk factors intervene. About 10% of patients with an idiopathic VTE will harbour an occult cancer. Half of these can probably be detected after a focused history, examination, routine blood tests and a chest x ray. The remaining cases may be diagnosed with an intensive screening protocol. About 60% of patients diagnosed on screening will have early disease, but we do not know whether screening improves the outcome. Evidence suggests that patients with cancer and a VTE should be treated with low-molecular-weight heparin, and treatment continued until the cancer is cured.

  • DVT, deep venous thrombosis
  • LMWH, low-molecular-weight heparin
  • VTE, venous thromboembolism

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.